Looking for a Genomind Alternative? Here's What to Know

You are looking for a Genomind alternative. Short answer: Gene2Rx covers the same core pharmacogenetic science (CPIC and FDA guidelines), does not require a provider order, works with 23andMe or AncestryDNA data you may already have, and costs $5 to $49 instead of several hundred dollars. Genomind's Genecept Assay includes some additional neuropsychiatric markers (SLC6A4, DRD2, MTHFR) with less established clinical actionability; Gene2Rx focuses on the genes where CPIC has published clinical guidelines and covers more medications outside psychiatry. See also our Gene2Rx vs GeneSight comparison if you're evaluating both psychiatric-focused tests.

Like GeneSight, Genomind's Genecept Assay must be ordered by a healthcare provider and requires a new DNA sample (cheek swab). If you have already had your DNA tested through 23andMe, AncestryDNA, or a whole-genome sequencing service, you are essentially paying to re-sequence variants you already have on file. Gene2Rx analyzes pharmacogenetic variants directly from your existing data. Consumer genotyping arrays are not clinical-grade assays and their raw data is labeled accordingly, but they reliably cover the core pharmacogenetic variants that CPIC guidelines are built around.

Genomind's pricing depends on insurance coverage and can be hard to pin down upfront. Out-of-pocket costs for clinical PGx tests like Genomind and GeneSight often run from several hundred dollars to over a thousand. If you already own your genetic data, a service that analyzes existing files is significantly less expensive and has no insurance complexity. Gene2Rx reports run $5 (starter), $35 (psychiatric focus), or $49 (full 110-medication report).

Genomind's panel is built around psychiatric and neurological prescribing. It includes the core drug-metabolizing enzymes but also some genes beyond standard pharmacokinetics, such as the serotonin transporter (SLC6A4), dopamine receptor (DRD2), and MTHFR. The clinical actionability of these additional markers is actively debated; major clinical laboratory and genetics societies have not adopted them into formal dosing guidelines. For medications outside psychiatry (statins, blood thinners, pain medications, chemotherapy), Genomind's coverage is limited.

All reputable pharmacogenetic tests, regardless of brand, analyze the same core drug-metabolizing enzyme genes (CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP3A5, CYP2B6, CYP1A2) using the same clinical guidelines from CPIC and the FDA. What differs between services is breadth of medication coverage, report format, cost, and whether a prescriber must be involved.

Whether you use Genomind, GeneSight, Gene2Rx, or another service, the pharmacogenetic genes with the strongest evidence are well-established. Here are the ones any good PGx test should cover.

When comparing PGx services, focus on the genes that matter for your actual medications. If you are primarily managing psychiatric medications, CYP2D6 and CYP2C19 are most important. If you also take cardiovascular drugs, pain medications, or statins, coverage of CYP2C9, SLCO1B1, and VKORC1 matters. Genomind's additional neuropsychiatric markers may provide supplementary information, but CPIC-guideline genes^[1] are where the strongest evidence lies.^[7]

Pharmacogenetic testing is valuable any time you are starting a medication with strong PGx evidence, if you have struggled to find the right psychiatric medication, or if you want a comprehensive genetic profile to inform future prescribing. Your genetics do not change, so one test covers you for life.

• Looking for a GeneSight Alternative? Here's the Short Answer
• 23andMe Pharmacogenetics: How to Get a Drug Response Report From Your Existing Data
• AncestryDNA for Drug Testing: Get Pharmacogenetics From Your Ancestry Data
• MyHeritage Pharmacogenetics: Use Your MyHeritage DNA for a Drug Response Report
• Nebula Genomics Pharmacogenetics: How to Get a Drug Response Report From Your WGS Data
• How Much Does a Pharmacogenetic Test Cost? 2026 Prices and Cheaper Alternatives

Gene2Rx analyzes the pharmacogenetic variants in your existing 23andMe, AncestryDNA, or VCF data, covering 110 medications across psychiatry, pain management, cardiology, and other drug classes, for $5 to $49. Genomind requires a provider order and a new cheek swab, focuses on psychiatric and neurological medications, and includes some neuropsychiatric markers (SLC6A4, DRD2, MTHFR) whose clinical actionability is debated. Genomind uses a clinical-grade assay; Gene2Rx interprets consumer data, which covers the core pharmacogenetic variants but is not clinical-grade.

Genomind's panel includes markers like SLC6A4, DRD2, ADRA2A, and MTHFR that go beyond standard drug metabolism. The clinical actionability of these is less established than the core pharmacokinetic genes (CYP2D6, CYP2C19, etc.) that every reputable service covers. Guideline-backed PGx recommendations mostly come from the drug-metabolizing enzyme genes.

MTHFR is included in some PGx panels, including Genomind's, because of its relationship to folate metabolism and potential mood effects. However, major clinical guidelines (including from CAP and ACMG) explicitly recommend against MTHFR genotyping for most clinical indications, because the research does not support using MTHFR variants to guide prescribing decisions. It is supplementary information rather than a primary driver of medication choices.

Yes. If you have already taken Genomind, those results are valid and useful. Gene2Rx can complement them by covering additional medications outside psychiatry (statins, blood thinners, pain medications) using your existing 23andMe or AncestryDNA data. The two reports together would give you the broadest pharmacogenetic picture without requiring a new Genomind test.